Oral therapies for diabetic hyperglycemia (Q34451776)

2 August 2017

1 reference

title

Oral therapies for diabetic hyperglycemia (English)

1 reference

2 August 2017

1 reference

Lebovitz HE

1

1 reference

2 August 2017

1 December 2001

1 reference

Endocrinology and Metabolism Clinics of North America

2 August 2017

1 reference

2 August 2017

30

1 reference

2 August 2017

909-933

1 reference

2 August 2017

4

1 reference

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

1 reference

7 January 2021

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

1 reference

7 January 2021

Comparative efficacy of a once-daily controlled-release formulation of glipizide and immediate-release glipizide in patients with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Diabetes, coronary heart disease and sulphonylureas-not the final word

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Undiagnosed NIDDM: clinical and public health issues.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Insulin resistance: definition and consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Insulin resistance and its treatment by thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Repaglinide versus glyburide: a one-year comparison trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

An overview of the safety and tolerance of glimepiride

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Glyburide enhances the responsiveness of the beta-cell to glucose but does not correct the abnormal patterns of insulin secretion in noninsulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Individual sulfonylureas and serious hypoglycemia in older people.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastro

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Rates of hypoglycemia in users of sulfonylureas.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Hepatic dysfunction associated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

The PPARs: from orphan receptors to drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970221-8

7 January 2021

10.1016/S0889-8529(05)70221-8

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11727405